dc.creatorLu, Wenzong
dc.creatorZhao, Chen
dc.creatorZhang, Liang
dc.creatorRen, Yumiao
dc.creatorNi, Yuan
dc.creatorPan, Haixian
dc.creatorMeng, Xiangyan
dc.creatorJia, Guangfeng
dc.date2012
dc.date2012-05-11T19:19:05Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/18090
dc.identifierhttp://www.latamjpharm.org/resumenes/31/2/LAJOP_31_2_1_6.pdf
dc.identifierissn:0326-2383
dc.descriptionThis study aimed to determine the effect of baicalin on insulin resistance, glucose absorption, and blood lipids in type 2 diabetic rat model. Diabetic rats were treated with baicalin (40, 80 mg/kg) for 40 days. The results showed that diabetic rats treated with baicalin resulted in a significant decrease in the concentration of plasma triglycerides and high-density lipoprotein cholesterol, improved the body weight. Furthermore, baicalin markedly decreased blood glucose level in the diabetic rats. The levels of plasma insulin and resistin exhibited significantly lower in the diabetic rats treated with baicalin than those of the model group. These findings suggest that baicalin can improve adipose metabolic disturbance in the experimental type 2 diabetic rats, can effectively ameliorate insulin resistance and plasma glucose transport by decreasing the levels of plasma resistin.
dc.descriptionColegio de Farmacéuticos de la Provincia de Buenos Aires
dc.formatapplication/pdf
dc.format214-219
dc.languageen
dc.relationLatin American Journal of Pharmacy
dc.relationvol. 31, no. 02
dc.subjectFarmacia
dc.titleBaicalin Normalizes Blood Glucose Level in Streptozotocin -induced Diabetic Rats
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución